The dementia of Alzheimer's type and brain ischemia are known to increase at comparable rates with age. Recent advances suggest that cerebral ischemia may contribute to the pathogenesis of Alzheimer's disease (AD), however, the neuropathological relationship between these two disorders is largely unclear. It has been demonstrated that axonopathy, mainly manifesting as impairment of axonal transport and swelling of the axon and varicosity, is a prominent feature in AD and may play an important role in the neuropathological mechanisms in AD. In this study, we investigated the early and chronic changes of the axons of neurons in the different brain areas (cortex, hippocampus and striatum) using in vivo tracing technique and grading analysis method in a rat model of transient focal cerebral ischemia/reperfusion (middle cerebral artery occlusion, MCAO). In addition, the relationship between the changes of axons and the expression of β-amyloid 42 (Aβ42) and hyperphosphorylated Tau, which have been considered as the key neuropathological processes of AD, was analyzed by combining tracing technique with immunohistochemistry or western blotting. Subsequently, we found that transient cerebral ischemia/reperfusion produced obvious swelling of the axons and varicosities, from 6 hours after transient cerebral ischemia/reperfusion even up to 4 weeks. We could not observe Aβ plaques or overexpression of Aβ42 in the ischemic brain areas, however, the site-specific hyperphosphorylated Tau could be detected in the ischemic cortex. These results suggest that transient cerebral ischemia/reperfusion induce early and chronic axonal changes, which may be an important mechanism affecting the clinical outcome and possibly contributing to the development of AD after stroke.
References
[1]
Kalaria R (2002) Similarities between Alzheimer's disease and vascular dementia. J Neurol Sci 203–204: 29–34.
[2]
Zhu X, Smith MA, Honda K, Aliev G, Moreira PI, et al. (2007) Vascular oxidative stress in Alzheimer disease. J Neurol Sci 257: 240–246.
[3]
McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939–944.
[4]
White L, Petrovitch H, Hardman J, Nelson J, Davis DG, et al. (2002) Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann N Y Acad Sci 977: 9–23.
[5]
de la Torre JC (2004) Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3: 184–190.
[6]
Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362: 329–344.
[7]
Troncoso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova O, et al. (2008) Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Ann Neurol 64: 168–176.
[8]
Koistinaho M, Koistinaho J (2005) Interactions between Alzheimer's disease and cerebral ischemia–focus on inflammation. Brain Res Rev 48: 240–250.
[9]
Arvanitakis Z, Leurgans SE, Barnes LL, Bennett DA, Schneider JA (2011) Microinfarct Pathology, Dementia, and Cognitive Systems. Stroke 42: 722–727.
[10]
Terry RD (1996) The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol 55: 1023–1025.
[11]
Neve RL, Robakis NK (1998) Alzheimer's disease: a re-examination of the amyloid hypothesis. Trends Neurosci 21: 15–19.
[12]
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353–356.
[13]
Armstrong RA (2011) The pathogenesis of Alzheimer's disease: a reevaluation of the “amyloid cascade hypothesis”. Int J Alzheimers Dis. 2011. 630865 p.
[14]
Dai J, Buijs RM, Kamphorst W, Swaab DF (2002) Impaired axonal transport of cortical neurons in Alzheimer's disease is associated with neuropathological changes. Brain Res 948: 138–144.
[15]
Stokin GB, Lillo C, Falzone TL, Brusch RG, et al. (2005) Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307: 1282–1288.
[16]
Wirths O, Weis J, Szczygielski J, Multhaup G, Bayer TA (2006) Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer's disease. Acta Neuropathol 111: 312–319.
[17]
Lazarov O, Morfini GA, Pigino G, Gadadhar A, Chen X, et al. (2007) Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1. J Neurosci 27: 7011–7020.
[18]
Smith KD, Kallhoff V, Zheng H, Pautler RG (2007) In vivo axonal transport rates decrease in a mouse model of Alzheimer's disease. Neuroimage 35: 1401–1408.
[19]
Minoshima S, Cross D (2008) In vivo imaging of axonal transport using MRI: aging and Alzheimer's disease. Eur J Nucl Med Mol Imaging 35(Suppl 1): S89–92.
[20]
Xiao A, He J, Wang Q, Luo Yi, Sun Y, et al. (2011) The origin and development of plaques and phosphorylated tau are associated with axonopathy in Alzheimer's disease. Neurosci Bull 27(5): 287–299.
[21]
Kalaria RN (2000) The role of cerebral ischemia in Alzheimer's disease. Neurobiol. Aging 21: 321–330.
[22]
Goedert M (1993) Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci 16: 460–465.
[23]
Longa EZ, Weinstein PR, Carison S, Cummins R (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20: 84–91.
[24]
van de Nes JA, Nafe R, Schlote W (2008) Non-tau based neuronal degeneration in Alzheimer's disease - an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex. Brain Res 1213: 152–165.
